Skip to content

What each GLP-1 is FDA-approved for

The approved uses, quoted from each label. Insurance and Medicare coverage often depends on which of these a prescription is for.

Zepbound injection

  • ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: dailymed.nlm.nih.gov, Sep 27, 2026
  • Indication 1: chronic weight management in adults with obesity, or overweight plus a weight-related comorbidity. to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.dailymed.nlm.nih.gov, Sep 27, 2026
  • Indication 2: moderate to severe obstructive sleep apnea in adults with obesity. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.dailymed.nlm.nih.gov, Sep 27, 2026
  • Limitation of use: not to be combined with other tirzepatide products or any GLP-1 receptor agonist. ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 8/2026. Full label

Wegovy injection

  • WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity: dailymed.nlm.nih.gov, Sep 27, 2026
  • Injection: reduce risk of major adverse CV events in adults with established CV disease and obesity/overweight. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.dailymed.nlm.nih.gov, Sep 27, 2026
  • to reduce excess body weight and maintain weight reduction long term in: dailymed.nlm.nih.gov, Sep 27, 2026
  • adults and pediatric patients aged 12 years and older with obesity. dailymed.nlm.nih.gov, Sep 27, 2026
  • adults with overweight in the presence of at least one weight-related comorbid condition. dailymed.nlm.nih.gov, Sep 27, 2026
  • Injection: noncirrhotic MASH with F2-F3 fibrosis (accelerated approval). for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)]. Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial.dailymed.nlm.nih.gov, Sep 27, 2026
  • Limitation of use (tablets and injection). Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 6/2026. Full label

Wegovy tablets

  • WEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity: dailymed.nlm.nih.gov, Sep 27, 2026
  • Tablets: reduce risk of major adverse CV events. to reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.dailymed.nlm.nih.gov, Sep 27, 2026
  • Tablets: chronic weight management in adults. to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition.dailymed.nlm.nih.gov, Sep 27, 2026
  • Limitation of use (tablets and injection). Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 6/2026. Full label

Foundayo tablets

  • Indication: chronic weight management in adults with obesity, or overweight plus a weight-related comorbidity. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. (1)dailymed.nlm.nih.gov, Sep 27, 2026
  • Limitation of use: not with another GLP-1 receptor agonist. Concomitant use with another GLP-1 receptor agonist is not recommended.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 7/2026. Full label

Ozempic injection

  • OZEMPIC is indicated: dailymed.nlm.nih.gov, Sep 27, 2026
  • Glycemic control in adults with type 2 diabetes. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.dailymed.nlm.nih.gov, Sep 27, 2026
  • Reduce MACE risk in type 2 diabetes with established CV disease. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.dailymed.nlm.nih.gov, Sep 27, 2026
  • Reduce kidney/CV risk in type 2 diabetes with CKD. to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 5/2026. Full label

Ozempic tablets

  • RYBELSUS and OZEMPIC tablets are indicated: dailymed.nlm.nih.gov, Sep 27, 2026
  • Glycemic control in adults with type 2 diabetes. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.dailymed.nlm.nih.gov, Sep 27, 2026
  • Reduce MACE risk in high-risk type 2 diabetes. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 1/2026. Full label

Mounjaro injection

  • MOUNJARO® is indicated: dailymed.nlm.nih.gov, Sep 27, 2026
  • Glycemic control in adults and children 10+ with type 2 diabetes. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.dailymed.nlm.nih.gov, Sep 27, 2026
  • Reduce MACE risk in high-risk adults with type 2 diabetes. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.dailymed.nlm.nih.gov, Sep 27, 2026

Label revised 8/2026. Full label

What Medicare covers depends on the use: Medicare GLP-1 Bridge. This page reports the labels; it is not medical advice. Medical disclaimer.